Summary:
- The article reports on clinical data for acoramidis, a therapeutic agent showing efficacy in treating transthyretin amyloid cardiomyopathy (ATTR-CM).
- The study highlights the drug's ability to stabilize cardiac structure, mitigate functional decline, and improve patient outcomes by significantly reducing hospitalization rates and increasing survival duration.